Search PubMed⌕ Search

PubMed · 16592079

On the Relation Between lambda Lines and Phase Separations.

Abstract

It has often been assumed that the slope of the isotherm involving a pair of secondary variable vanishes along a lambda line [for example, along a lambda line in the pressure-volume plane ([unk]P/[unk]V)(T) vanishes], and therefore that the specific heat for constant extensive variable (e.g., C(V)) has the greatest possible value on the lambda line and so obeys the Buckingham-Fairbank relation. It is shown here by a heuristic theoretical argument that in (3)He-(4)He solutions ([unk]mu(4)/[unk]x(3))(T) and ([unk]mu(3)/[unk]x(3))(T) probably do not vanish and C(x3) does not have its maximum possible value, although it may become infinite when x(3) --> 0. (mu(4) and mu(3) are chemical potentials of (4)He and (3)He and x(3) is the molefraction of (3)He). Only at the tricritical point does ([unk]mu(4)/[unk]x(3))(T) finally vanish and C(x3) have a value, which cannot be exceeded without the system's becoming unstable. In the case of the transition in solid NH(4)Cl the experimental facts seem to indicate that at the higher temperatures, where the transition is of higher order, ([unk]P/[unk]V)(T) does not become zero along the transition line. A statistical thermodynamic description of tricritical points is given, and shown to accord qualitatively with the experimental results for the (3)He-(4)He solutions. There is evidence that any singular behavior at the tricritical point in (3)He-(4)He is already present along the lambda line. Finally, an analysis is made of the possible behavior of binary liquid solutions, and it is shown that a tendency of C(V) to exceed its maximum value can result in a flat top on the coexistence curve.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O K Rice. 1973. On the Relation Between lambda Lines and Phase Separations.. https://doi.org/10.1073/pnas.70.4.1241

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗